

Press Release

Martin Kunze

Corporate Communications

Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2115 F +49 6172 608-2294 martin.kunze@fresenius.com www.fresenius.com

March 6, 2018

Potentialpark study 2018 shows Fresenius provides Germany's best online offering for job applicants

For the seventh straight time, the market research institute Potentialpark has honored the global healthcare group Fresenius as the German company with the best overall Internet offering for job applicants.

In its just-released study for 2018, Potentialpark also put Fresenius first in two individual categories – Online Application Management and Mobile. The company was rated second in the Career Website category, and third for Social Media.

Potentialpark has carried out an annual study of German companies' online offerings for job applicants since 2002. For this year's study, Potentialpark assessed the online activities of 141 German companies according to more than 300 criteria. Some 38,000 students and graduates around the world participated.

"Digital channels are hugely important to our potential applicants – and that makes them essential for us," said Markus Olbert, Senior Vice President for Corporate Human Resources at Fresenius. "For us, these awards from Potentialpark are both an indicator and a motivator to continually improve. For example, we recently overhauled our job search, and in combination with some additional optimizations to our digital channels we were able to increase the number of completed applications by about 25 percent."

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2017, Group sales were €34 billion. On December 31, 2017, the Fresenius Group had 273,249 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

Follow us on Facebook and Twitter: www.facebook.com/fresenius.group and http://www.twitter.com/fresenius.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey, Dr. Jürgen Götz,

Mats Henriksson, Rice Powell, Dr. Ernst Wastler Chairman of the Supervisory Board: Dr. Gerd Krick